Emerging links between non-neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: A systematic review. (Q38550856)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 July 2015

Language	Label	Description	Also known as
English	Emerging links between non-neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: A systematic review.	scientific article published on 20 July 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference

Europe PubMed Central

Emerging links between non-neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: A systematic review (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

metabolic syndrome

1 reference

based on heuristic

inferred from title

Sandro La Vignera

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Giuseppe Morgia

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

author name string

Giorgio I Russo

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Tommaso Castelli

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Daniele Urzì

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Salvatore Privitera

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Rosita A Condorelli

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Aldo E Calogero

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Vincenzo Favilla

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Sebastiano Cimino

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

20 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

International Journal of Urology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

982-990

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Effects of Serenoa repens, selenium and lycopene (Profluss®) on chronic inflammation associated with benign prostatic hyperplasia: results of "FLOG" (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Overactive bladder: Is there a link to the metabolic syndrome in men?

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Antioxidant mechanism of heme oxygenase-1 involves an increase in superoxide dismutase and catalase in experimental diabetes

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Lower likelihood of having moderate-to-severe lower urinary tract symptoms in middle-aged healthy Korean men with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Association between metabolic syndrome and male lower urinary tract symptoms in Japanese subjects using three sets of criteria for metabolic syndrome and International Prostate Symptom Score

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from a Chinese male population survey

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Association of metabolic syndrome and benign prostate enlargement in young korean males

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Relationship between lower urinary tract symptoms and metabolic syndrome in a community-based elderly population

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

A prospective study of alcohol, diet, and other lifestyle factors in relation to obstructive uropathy

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Relationships between Prostate-Specific Antigen, Prostate Volume, and Components of Metabolic Syndrome in Healthy Korean Men.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Metabolic syndrome associated with reduced lower urinary tract symptoms in middle-aged men receiving health checkup

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Association between metabolic syndrome and severity of lower urinary tract symptoms (LUTS): an observational study in a 4666 European men cohort

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Relationship between metabolic syndrome and prostate volume in Korean men under 50 years of age.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III).

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Metabolic factors associated with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Risk factors for lower urinary tract symptoms in a population-based sample of African-American men.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Metabolic syndrome and accompanying hyperinsulinemia have favorable effects on lower urinary tract symptoms in a generally healthy screened population

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Metabolic syndrome and lower urinary tract symptoms in patients with benign prostatic enlargement: a possible link to storage symptoms.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Insulin resistance is an independent predictor of severe lower urinary tract symptoms and of erectile dysfunction: results from a cross-sectional study.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Relationship between non-alcoholic fatty liver disease and benign prostatic hyperplasia/lower urinary tract symptoms: new insights from an Italian cross-sectional study.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Insulin-like growth factor I, insulin-like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Nutrition, insulin, insulin-like growth factors and cancer

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Type 2 diabetes but not metabolic syndrome is associated with an increased risk of lower urinary tract symptoms and erectile dysfunction in men aged <45 years.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Diabetes and benign prostatic hyperplasia progression in Olmsted County, Minnesota

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Increase of Framingham cardiovascular disease risk score is associated with severity of lower urinary tract symptoms.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Central obesity as a risk factor for prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Correlation between lipid profile and heme oxygenase system in patients with benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Benign prostatic hyperplasia: a new metabolic disease?

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Metabolic syndrome and lower urinary tract symptoms: the role of inflammation.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

The association of eNOS G894T polymorphism with metabolic syndrome and erectile dysfunction

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinic

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Diabetes severity, metabolic syndrome, and the risk of erectile dysfunction.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Metabolic syndrome correlates with peri-urethral fibrosis secondary to chronic prostate inflammation: evidence of a link in a cohort of patients undergoing radical prostatectomy

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Periurethral fibrosis secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort study.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Obesity-induced diabetes and lower urinary tract fibrosis promote urinary voiding dysfunction in a mouse model

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

BPH/LUTS and ED: common pharmacological pathways for a common treatment.

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FIJU.12877

21 January 2018

Identifiers

10.1111/IJU.12877

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26193757%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38550856&oldid=1625174040"